Precigen stock rating reiterated as Overweight by Cantor Fitzgerald

Published 26/09/2025, 12:32
Precigen stock rating reiterated as Overweight by Cantor Fitzgerald

Investing.com - Cantor Fitzgerald has reiterated an Overweight rating on Precigen Inc. (NASDAQ:PGEN) following the company’s recent preferred stock conversion. The stock has shown remarkable momentum, delivering a 211% return year-to-date, with the current price of $3.48 sitting well above its 52-week low of $0.65.

The firm maintained its positive stance on the biotechnology company after updating its financial model to account for Precigen’s recent corporate action. According to InvestingPro data, analysts have set price targets ranging from $8.00 to $8.50, suggesting significant potential upside from current levels.

The model update reflects Precigen’s conversion of its 8.00% Series A Convertible Perpetual Preferred Stock into 54.9 shares of common stock, which was completed on September 17, 2025.

Cantor Fitzgerald noted that this conversion represents a significant change to Precigen’s capital structure that warranted a revision to their financial projections.

The preferred stock conversion was delivered as scheduled last week, finalizing a transaction that impacts the company’s outstanding share count and dividend obligations.

In other recent news, Precigen, Inc. has announced the conversion of 79,000 shares of its 8.00% Series A Convertible Perpetual Preferred Stock into approximately 54.9 million common shares, with an aggregate stated value of $79 million. This conversion was conducted under the terms of the company’s Amended and Restated Articles of Incorporation and did not involve any commissions or remuneration for solicitation. Precigen also secured $100 million in non-dilutive financing through a credit facility agreement with Pharmakon Advisors, LP, with the potential to access an additional $25 million by March 2027. This financing bears interest at a variable rate and will mature five years after closing.

On the analyst front, Cantor Fitzgerald has reiterated its Overweight rating for Precigen, maintaining a positive outlook despite recent share price fluctuations. Similarly, H.C. Wainwright has reiterated its Buy rating and $8.50 price target following the FDA’s early approval of Papzimeos for treating recurrent respiratory papillomatosis. Precigen has also set a wholesale acquisition cost of $460,000 for a full treatment cycle of Papzimeos. Additionally, the company has signed a supply agreement with Catalent Maryland, Inc. for the commercial manufacturing of PAPIZEMOS, effective August 2025. This agreement ensures that Catalent will handle various services related to the product’s manufacturing and maintenance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.